Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Financial Select Sector SPDR Fund (XLF) Price & Performance

AbCellera Biologics IncTrade
Financial Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Financial Select Sector SPDR Fund — how do they compare? AbCellera Biologics Inc trades at $9.99 (market cap $2.99B), while Financial Select Sector SPDR Fund trades at $57.88. Which is the better fit depends on your goals.

ABCLXLF
Market Cap
$2.99B
Sector
Health
52-Week High
$9.76$58.01
52-Week Low
$2.78$47.80
Enterprise Value
$2.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Financial Select Sector SPDR Fund

XLF, the Financial Select Sector SPDR ETF, trades at $57.73, down 0.14% on the day, with a bullish technical signal driven by moving averages. The ETF recently crossed above its 200-day moving average and hit a record high, supported by strong inflows into sector ETFs. A dividend of $0.19 is scheduled for June 2026.

Outlook remains positive given sector momentum and AI-driven opportunities, though overbought RSI levels and concentration risks warrant caution. Financials benefit from robust bank earnings and market broadening, but interest rate sensitivity and valuation pressures pose headwinds.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Financial Select Sector SPDR Fund

The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.

Read more on XLF